# US 2026/0027153 A1 · Therapeutic polynucleotides encoding t cell receptor (tcr) alpha chain polypeptides and/or tcr beta chain polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027153 A1
- Document ID: US20260027153A1
- Status: Published application
- Kind: A1
- Application number: 19/144,090
- Filed: 2024-01-16
- Published: 2026-01-29
- Earliest claimed: 2023-01-17
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Dino Di Carlo; Owen N. Witte; Doyeon Koo; Zhiyuan Mao
- Web page: https://patentgrep.com/patent/US20260027153A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- B01J 13/14: Polymerisation; cross-linking
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4242: {Transcription factors, e.g. SOX or c-MYC}
- A61K 40/46: Viral antigens
- B01J 13/20: After-treatment of capsule walls, e.g. hardening
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/088: {Varicella-zoster virus}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/246: {IL-2}
- C07K 16/249: {Interferons}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2815: {against CD8}
- C07K 16/289: {against CD45}
- C07K 16/30: from tumour cells
- C12N 5/0636: {T lymphocytes}
- C12N 15/85: for animal cells
- C12Q 1/6851: Quantitative amplification
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 33/505: {involving T-cells}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C12N 2513/00: 3D culture
- C12N 2535/00: Supports or coatings for cell culture characterised by topography
- C12Q 2600/158: Expression markers
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- G01N 2333/525: Tumor necrosis factor [TNF]
- G01N 2333/55: IL-2
- G01N 2333/57: IFN-gamma
- G01N 2333/96436: Granzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods and materials for the preparation of immune cells, including T cells engineered to express exogenous T cell receptors that target polypeptides associated with human leukocyte antigens. Embodiments of the invention include polynucleotides encoding T cell receptors that target human MEAF6 and SCAMP3 polypeptides, and engineered T cells transduced with these polynucleotides. Embodiments of the invention include polynucleotides encoding T cell receptors that target cytomegalovirus and Epstein Barr virus polypeptides, and engineered T cells transduced with these polynucleotides. Embodiments of the invention also include methods of making and using such polynucleotides and engineered T cells.

## Claims

### Claim 1

A composition of matter comprising a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and/or a TCR beta chain polypeptide; wherein the polynucleotide is disposed in a vector, and when the vector is transduced into a CD8+ T cell, the TCR alpha chain polypeptide and/or the TCR beta chain polypeptide encoded by the polynucleotide form a T cell receptor on the CD8+ T cell that recognizes a polypeptide epitope present in a human MYST/Esa1 associated factor 6 (MEAF6) splicing variant polypeptide.

### Claim 2 (depends on 1)

The composition of claim 1, wherein:
the T cell receptor recognizes a polypeptide epitope present in a human MYST/Esa1 associated factor 6 (MEAF6) splicing variant polypeptide in combination with a human leukocyte antigen HLA-A;
the T cell receptor recognizes a polypeptide epitope present in: SGMFDYDFEYV (SEQ ID NO: 131); or GMFDYDFEYV (SEQ ID NO: 135);
the polynucleotide encodes a segment of at least 10 amino acids having an at least 98% sequence identity to NVTCR21 (SEQ ID NO: 121 and/or SEQ ID NO: 124);
the polynucleotide encodes amino acids of a TCR variable region and the vector comprises vector polynucleotides encoding a TCR constant region fused in frame with the TCR variable region; and/or
the polynucleotide is disposed in a cell.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the cell is a human CD8+ T cell.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the cell is a CD8+ T cell obtained from an individual diagnosed with a cancer that expresses a human MEAF6 splicing variant; and the CD8+ T cell is transduced with a vector comprising a polynucleotide encoding a TCR Vα polypeptide in combination with a polynucleotide encoding a TCR Vβ polypeptide such that a heterologous TCR is expressed on a surface of the CD8+ T cell, wherein the heterologous TCR recognizes a MEAF6 splicing variant peptide associated with a human leukocyte antigen expressed on the surface of cells of the cancer.

### Claim 5

A method of inhibiting growth of a prostate cancer cell or lung cancer cell comprising:
combining the prostate cancer cell or the lung cancer cell with a CD8+ T cell transduced with a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and a TCR beta chain polypeptide; wherein when transduced into and expressed in the CD8+ T cell, the alpha chain polypeptide and the TCR beta chain polypeptide can form a T cell receptor that recognizes a polypeptide epitope present in a human MYST/Esa1 associated factor 6 (MEAF6) splicing variant expressed on the prostate cancer cell or the lung cancer cell, thereby inhibiting growth of the prostate cancer cell or the lung cancer cell.

### Claim 6

A composition of matter comprising a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and/or a TCR beta chain polypeptide; wherein the polynucleotide is disposed in a vector, and when the vector is transduced into a CD8+ T cell, the TCR alpha chain polypeptide and/or the TCR beta chain polypeptide encoded by the polynucleotide form a T cell receptor on the CD8+ T cell that recognizes a polypeptide epitope present in a human secretory carrier-associated membrane protein 3 (SCAMP3) polypeptide.

### Claim 7 (depends on 6)

The composition of claim 6, wherein:
the T cell receptor recognizes a polypeptide epitope present in STMYYLWML (SEQ ID NO 133);
the T cell receptor recognizes a polypeptide epitope of SCAMP3 in combination with a human leukocyte antigen HLA-A*02:01;
the polynucleotide encodes amino acids of a TCR variable region and the vector comprises vector polynucleotides encoding a TCR constant region fused in frame with the TCR variable region;
the polynucleotide encodes a segment of at least 10 amino acids of a TCR variable region having an at least 98% sequence identity to NVTCR11 (SEQ ID NO: 119 and/or SEQ ID NO: 122); or NVTCR19 (SEQ ID NO: 120 and/or SEQ ID NO: 123); and/or
the polynucleotide is disposed in a cell.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the cell is a human CD8+ T cell.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the cell is a CD8+ T cell obtained from an individual diagnosed with a cancer that expresses a human SCAMP3 polypeptide; and the CD8+ T cell is transduced with a vector comprising a polynucleotide encoding a TCR Vα polypeptide in combination with a polynucleotide encoding a TCR Vβ polypeptide such that a heterologous TCR is expressed on a surface of the CD8+ T cell, wherein the heterologous TCR recognizes a SCAMP3 polypeptide associated with a human leukocyte antigen expressed on the surface of cells of the cancer.

### Claim 10

A method of inhibiting growth of a breast cancer cell, a glioma cell or a hepatocarcinoma cell comprising:
combining the breast cancer cell, the glioma cell or the hepatocarcinoma cell with a CD8+ T cell transduced with a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and a TCR beta chain polypeptide; wherein when transduced into and expressed in the CD8+ T cell, the alpha chain polypeptide and the TCR beta chain polypeptide can form a T cell receptor that recognizes a polypeptide epitope present in a SCAMP3 polypeptide expressed on the breast cancer cell, the glioma cell or the hepatocarcinoma cell, thereby inhibiting growth of the breast cancer cell, the glioma cell or the hepatocarcinoma cell.

### Claim 11

A composition of matter comprising a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and/or a TCR beta chain polypeptide; wherein the polynucleotide is disposed in a vector, and when the vector is transduced into a CD8+ T cell, the TCR alpha chain polypeptide and/or the TCR beta chain polypeptide encoded by the polynucleotide form a T cell receptor on the CD8+ T cell that recognizes a polypeptide epitope present in a cytomegalovirus (CMV) polypeptide.

### Claim 12 (depends on 11)

The composition of claim 11, wherein:
the T cell receptor recognizes a polypeptide epitope present in NLVPMVATV (SEQ ID NO 2) or VLEETSVML (SEQ ID NO 3);
the T cell receptor recognizes a polypeptide epitope of CMV in combination with a human leukocyte antigen HLA-A*02:01;
the polynucleotide encodes amino acids of a TCR variable region and the vector comprises vector polynucleotides encoding a TCR constant region fused in frame with the TCR variable region; and/or
the polynucleotide is disposed in a cell.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the polynucleotide encodes a segment of at least 10 amino acids amino acids of a TCR variable region having an at least 98% sequence identity to amino acids of TCR1 (SEQ ID NO: 55 and/or SEQ ID NO: 87), TCR2 (SEQ ID NO: 56 and/or SEQ ID NO: 88), TCR3 (SEQ ID NO: 57 and/or SEQ ID NO: 89), TCR4 (SEQ ID NO: 58 and/or SEQ ID NO: 90), TCR5 (SEQ ID NO: 59 and/or SEQ ID NO: 91), TCR6 (SEQ ID NO: 60 and/or SEQ ID NO: 92), TCR8 (SEQ ID NO: 62 and/or SEQ ID NO: 94), TCR9 (SEQ ID NO: 63 and/or SEQ ID NO: 95), TCR12 (SEQ ID NO: 66 and/or SEQ ID NO: 98), TCR13 (SEQ ID NO: 67 and/or SEQ ID NO: 99), TCR14 (SEQ ID NO: 68 and/or SEQ ID NO: 100), TCR15 (SEQ ID NO: 69 and/or SEQ ID NO: 101), TCR17 (SEQ ID NO: 71 and/or SEQ ID NO: 103), TCR21 (SEQ ID NO: 75 and/or SEQ ID NO: 107), TCR22 (SEQ ID NO: 76 and/or SEQ ID NO: 108), TCR23 (SEQ ID NO: 77 and/or SEQ ID NO: 109), TCR24 (SEQ ID NO: 78 and/or SEQ ID NO: 110), or TCR25 (SEQ ID NO: 79 and/or SEQ ID NO: 111).

### Claim 14 (depends on 13)

The composition of claim 13, wherein the cell is a CD8+ T cell obtained from an individual having undergone a stem cell transplantation and diagnosed with a CMV infection; and the CD8+ T cell is transduced with a vector comprising a polynucleotide encoding a TCR Vα polypeptide in combination with a polynucleotide encoding a TCR Vβ polypeptide such that a heterologous TCR is expressed on a surface of the CD8+ T cell, wherein the heterologous TCR recognizes a CMV polypeptide associated with a human leukocyte antigen expressed on the surface of cells infected with CMV.

### Claim 15

A method of inhibiting cytomegalovirus (CMV) growth comprising:
combining a human cell infected with CMV with a CD8+ T cell transduced with a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and a TCR beta chain polypeptide; wherein when transduced into and expressed in the CD8+ T cell, the alpha chain polypeptide and the TCR beta chain polypeptide can form a T cell receptor that recognizes a polypeptide epitope present in a cytomegalovirus, thereby inhibiting growth of the cytomegalovirus.

### Claim 16

A composition of matter comprising a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and/or a TCR beta chain polypeptide; wherein the polynucleotide is disposed in a vector, and when the vector is transduced into a CD8+ T cell, the TCR alpha chain polypeptide and/or the TCR beta chain polypeptide encoded by the polynucleotide form a T cell receptor on the CD8+ T cell that recognizes a polypeptide epitope present in a Epstein Barr virus (EBV) polypeptide.

### Claim 17 (depends on 16)

The composition of claim 16, wherein:
the T cell receptor recognizes a polypeptide epitope present in GLCTLVAML (SEQ ID NO 4);
the T cell receptor recognizes a polypeptide epitope of EBV in combination with a human leukocyte antigen HLA-A*02:01;
the polynucleotide encodes amino acids of a TCR variable region and the vector comprises vector polynucleotides encoding a TCR constant region fused in frame with the TCR variable region; and/or
the polynucleotide is disposed in a cell.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the polynucleotide encodes a segment of at least 10 amino acids amino acids of a TCR variable region having an at least 98% sequence identity to amino acids of TCR7 (SEQ ID NO: 61 and/or SEQ ID NO: 93), TCR10 (SEQ ID NO: 64 and/or SEQ ID NO: 96), TCR11 (SEQ ID NO: 65 and/or SEQ ID NO: 97), TCR16 (SEQ ID NO: 60 and/or SEQ ID NO: 70), TCR18 (SEQ ID NO: 60 and/or SEQ ID NO: 72), TCR19 (SEQ ID NO: 73 and/or SEQ ID NO: 105), TCR20 (SEQ ID NO: 74 and/or SEQ ID NO: 106), or TCR32 (SEQ ID NO: 86 and/or SEQ ID NO: 118).

### Claim 19 (depends on 18)

The composition of claim 18, wherein the cell is a CD8+ T cell obtained from an individual diagnosed with a head carcinoma or a neck carcinoma; and the CD8+ T cell is transduced with a vector comprising a polynucleotide encoding a TCR Vα polypeptide in combination with a polynucleotide encoding a TCR Vβ polypeptide such that a heterologous TCR is expressed on a surface of the CD8+ T cell, wherein the heterologous TCR recognizes a EBV polypeptide associated with a human leukocyte antigen expressed on the surface of cells infected with EBV.

### Claim 20

A method of inhibiting Epstein Barr virus (EBV) growth comprising:
combining a human cell infected with EBV with a CD8+ T cell transduced with a polynucleotide encoding a T cell receptor (TCR) alpha chain polypeptide and a TCR beta chain polypeptide; wherein when transduced into and expressed in the CD8+ T cell, the alpha chain polypeptide and the TCR beta chain polypeptide can form a T cell receptor that recognizes a polypeptide epitope present in a Epstein Barr virus, thereby inhibiting growth of the Epstein Barr virus.
